Skip to main content

Cerevel Therapeutics Holdings, Inc.

CEREInactive ticker
Industry
Pharmaceutical Preparations
SEC CIK
0001805387

No open-market purchases or sales by Cerevel Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cerevel Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cerevel Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cerevel Therapeutics Holdings, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bain Capital Investors LLCDirector, 10% Owner0IndirectAug 5, 20240
Bain Capital Fund XII, LPDirector, 10% Owner0IndirectAug 5, 20240
BCPE Perception GP, LLCDirector, 10% Owner0IndirectAug 5, 20240
BC Perception Holdings, LPDirector, 10% Owner0IndirectAug 5, 20240
Bain Capital Partners XII, LLCDirector, 10% Owner0IndirectAug 5, 20240
Pfizer IncOther: Former 10% Owner0Aug 5, 20240
Patrick Deval LDirector0Aug 5, 20240
Riedel Norbert GDirector0Aug 5, 20240
Coles N AnthonyDirector0Aug 5, 20240
Dekkers Marijn EDirector0IndirectAug 5, 20240
Sulzberger GabrielleDirector0Aug 5, 20240
Renaud Ronald C JRPresident & CEO0IndirectAug 5, 20240
Giordano Douglas E.Director0Aug 5, 20240
Gordon Christopher RDirector, 10% Owner0IndirectAug 5, 20240
Mckernan RuthDirector0Aug 5, 20240
DiPietro KennethChief Human Resources Officer0Aug 5, 20240
Koppel AdamDirector, 10% Owner0IndirectAug 5, 20240
Burgess Paul D.See Remarks0Aug 5, 20240
Akamine ScottChief Legal Officer0Aug 5, 20240
ALTSCHULLER SusanChief Financial Officer0Aug 5, 20240
Sanchez RamiroChief Medical Officer0Aug 5, 20240
Renger JohnChief Scientific Officer0Aug 5, 20240
Bodenrader MarkSee Remarks0Aug 5, 20240
Tregoning KathleenSee Remarks0Aug 5, 20240
Edelman JosephDirector0IndirectFeb 21, 20240
Perceptive Advisors LLCDirector0IndirectFeb 21, 20240
Perceptive Life Sciences Master Fund LtdDirector0IndirectFeb 21, 20240
Ceesay AbrahamPresident0Feb 8, 20230
PF Equity Holdings 1 B.V.10% Owner0Apr 4, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 3, 2024 (view filing)Jul 12 daysColes N AnthonyDirectorSSale−25.0K$41.18−$1.03M−49.1%25.9K after10b5-1
Jun 5, 2024 (view filing)Jun 32 daysColes N AnthonyDirectorSSale−50.0K$40.61−$2.03M−76.2%15.6K after10b5-1
May 14, 2024 (view filing)May 104 daysColes N AnthonyDirectorSSale−50.0K$42.10−$2.10M−76.2%15.6K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysColes N AnthonyDirectorSSale−50.0K$42.33−$2.12M−76.2%15.6K after10b5-1
Mar 6, 2024 (view filing)Mar 42 daysColes N AnthonyDirectorSSale−50.0K$41.01−$2.05M−76.2%15.6K after10b5-1
Mar 4, 2024 (view filing)Feb 294 daysColes N AnthonyDirectorSSale−50.0K$41.16−$2.06M−76.2%15.6K after10b5-1
Feb 8, 2024 (view filing)Feb 71 dayRenger JohnChief Scientific OfficerSSale−2.16K$41.54−$89.8K−25.3%6.37K after
Feb 8, 2024 (view filing)Feb 71 dayColes N AnthonyDirectorSSale−2.51K$41.54−$104.1K−13.8%15.6K after
Jan 4, 2024 (view filing)Jan 22 daysColes N AnthonyDirectorSSale−50.0K$42.24−$2.11M−94.9%2.70K after10b5-1
Dec 28, 2023 (view filing)Dec 262 daysSanchez RamiroChief Medical OfficerSSale−10.0K$42.47−$424.7K−40.5%14.7K after10b5-1
Dec 27, 2023 (view filing)Dec 225 daysDiPietro KennethChief Human Resources OfficerSSale−8.00K$41.45−$331.6K−24.5%24.7K after
Dec 21, 2023 (view filing)Dec 201 dayBodenrader MarkSee RemarksSSale−7.89K$41.42−$326.8K−30.8%17.7K after
Dec 21, 2023 (view filing)Dec 201 dayDiPietro KennethChief Human Resources OfficerSSale−6.26K$41.42−$259.1K−20.2%24.7K after
Dec 21, 2023 (view filing)Dec 201 dayAkamine ScottChief Legal OfficerSSale−7.07K$41.42−$292.9K−49.4%7.24K after
Dec 21, 2023 (view filing)Dec 201 daySanchez RamiroChief Medical OfficerSSale−10.2K$41.42−$420.5K−40.9%14.7K after
Dec 21, 2023 (view filing)Dec 201 dayALTSCHULLER SusanChief Financial OfficerSSale−13.8K$41.42−$571.9K−44.9%16.9K after
Dec 21, 2023 (view filing)Dec 201 dayTregoning KathleenSee RemarksSSale−6.29K$41.42−$260.4K−45.6%7.52K after
Dec 19, 2023 (view filing)Dec 154 daysSanchez RamiroChief Medical OfficerSSale−7.50K$41.39−$310.4K−100.0%0 after
Dec 11, 2023 (view filing)Dec 74 daysSanchez RamiroChief Medical OfficerSSale−10.0K$41.37−$413.7K−100.0%0 after10b5-1
Dec 7, 2023 (view filing)Dec 5-72 daysAkamine ScottChief Legal OfficerSSale−17.5K$38.64−$676.2K−97.2%513 after2 lots10b5-1
Nov 16, 2023 (view filing)Nov 142 daysColes N AnthonyDirectorSSale−22.8K$25.13−$573.6K−89.4%2.70K after
Nov 9, 2023 (view filing)Nov 7-82 daysColes N AnthonyDirectorSSale−27.2K$25.02−$680.0K−91.0%2.70K after2 lots
Nov 6, 2023 (view filing)Nov 2-34 daysColes N AnthonyDirectorSSale−100.0K$25.34−$2.53M−97.4%2.70K after2 lots
Nov 3, 2023 (view filing)Nov 12 daysPatrick Deval LDirectorSSale−30.1K$25.00−$753.3K−90.2%3.28K after
Oct 18, 2023 (view filing)4:30 PM ETOct 162 daysBain Capital Investors LLC and 4 others10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M afterDuplicate filing
Oct 18, 2023 (view filing)Oct 162 daysKoppel AdamDirector, 10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M afterDuplicate filing
Oct 18, 2023 (view filing)Oct 162 daysGordon Christopher RDirector, 10% OwnerPPurchase+5.48M$22.81+$125.0M+9.1%65.7M after
Oct 17, 2023 (view filing)4:53 PM ETOct 161 dayEdelman Joseph and 2 othersDirectorPPurchase+876.8K$22.81+$20.0M+8.8%10.8M after
Sep 8, 2023 (view filing)Sep 71 dayColes N AnthonyDirectorSSale−50.0K$24.07−$1.20M−94.9%2.70K after
Aug 7, 2023 (view filing)Aug 34 daysRenaud Ronald C JRPresident & CEOPPurchase+83.9K$23.96+$2.01MNew position83.9K after
Aug 7, 2023 (view filing)Aug 43 daysBurgess Paul D.See RemarksPPurchase+21.9K$22.93+$501.7KNew position21.9K after
Jul 13, 2023 (view filing)Jul 112 daysColes N AnthonyDirectorSSale−50.0K$30.03−$1.50M−94.9%2.70K after10b5-1
Jun 20, 2023 (view filing)Jun 155 daysDekkers Marijn EDirectorSSale−200.0K$34.43−$6.89M−33.2%402.3K after
Jun 5, 2023 (view filing)Jun 14 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$32.60−$1.63M−94.9%2.70K after10b5-1
Jun 5, 2023 (view filing)Jun 23 daysBodenrader MarkSee RemarksSSale−1.90K$32.95−$62.4K−25.5%5.52K after10b5-1
May 8, 2023 (view filing)May 44 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$31.47−$1.57M−94.9%2.70K after3 lots10b5-1
Apr 13, 2023 (view filing)Apr 112 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$25.06−$1.25M−94.9%2.70K after10b5-1
Mar 6, 2023 (view filing)Mar 2-34 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$27.11−$1.36M−94.9%2.70K after2 lots
Feb 8, 2023 (view filing)Feb 71 dayColes N AnthonyCEO and ChairpersonSSale−50.0K$33.12−$1.66M−94.9%2.70K after2 lots
Jan 6, 2023 (view filing)Jan 51 dayColes N AnthonyCEO and ChairpersonSSale−50.0K$29.94−$1.50M−94.9%2.70K after2 lots
Dec 13, 2022 (view filing)Dec 94 daysColes N AnthonyCEO and ChairpersonSSale−50.0K$26.67−$1.33M−94.9%2.70K after2 lots
Nov 3, 2022 (view filing)Nov 12 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−90.2%2.70K after
Oct 6, 2022 (view filing)Oct 42 daysRenger JohnChief Scientific OfficerSSale−25.0K$30.00−$750.0K−90.2%2.70K after
Sep 14, 2022 (view filing)Sep 122 daysPatrick Deval LDirectorSSale−47.7K$30.78−$1.47M−100.0%0 after
Sep 12, 2022 (view filing)Sep 84 daysCeesay AbrahamPresidentSSale−19.2K$32.50−$624.3K−100.0%0 after
Aug 24, 2022 (view filing)Aug 222 daysCeesay AbrahamPresidentSSale−9.61K$32.50−$312.2K−100.0%0 after
Aug 18, 2022 (view filing)5:10 PM ETAug 162 daysEdelman Joseph and 2 othersDirectorPPurchase+1.43M$35.00+$49.9M+28.0%6.51M after
Aug 18, 2022 (view filing)5:10 PM ETAug 162 daysEdelman Joseph and 2 othersDirectorPPurchase+2.16M–––DerivativePrice outlier
Aug 17, 2022 (view filing)Aug 152 daysCeesay AbrahamPresidentSSale−9.61K$34.12−$327.8K−100.0%0 after
Aug 12, 2022 (view filing)Aug 102 daysRenger JohnChief Scientific OfficerSSale−55.0K$40.50−$2.23M−95.3%2.70K after2 lots